Coexisting psoriasis affects the clinical course of type 1 diabetes in children

Michalak, Arkadiusz; Koptas, Marta; Świercz, Aleksandra; Wyka, Krystyna; Hogendorf, Anna; Szadkowska, Agnieszka; Młynarski, Wojciech; Fendler, Wojciech

doi:10.18544/pedm-23.03.0085

Cited by 1 publication

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although, most of the most frequent signs and symptoms are seen in type 2 diabetes and are related to insulin resistance, some typical lesions may occur in T1D as well, such as necrobiosis lipoidica diabeticorum or diabetic dermopathy [138,139]. Even though there is wider evidence for a link between psoriasis and type 2 diabetes, this condition may also be related to T1D [32,140], especially in obese patients [141]. The prevalence of psoriasis was evaluated in a cohort of 166 children, finding a fourfold increase compared to the general population [33].…”

Section: Atrophic Gastritis and Inflammatory Bowel Diseasesmentioning

confidence: 99%

Type 1 Diabetes and Other Autoimmune Disorders in Children

Grasso,

Chiarelli

2024

Pediatric Diabetes

View full text Add to dashboard Cite

The incidence of autoimmune disorders (AIDs) has been dramatically increasing in both children and adults over the past few years, and type 1 diabetes (T1D) is one of the diseases that has seen the highest growth. It is well-known that the dysimmune process may spread to other systems, leading to the onset of one or more AIDs in the same individual; however, the relationship between AIDs is not often recognized. The most frequently diagnosed AIDs in children and adolescents with T1D are thyroid diseases and celiac disease, but it is also important to consider the onset of the other conditions, such as juvenile idiopathic arthritis, multiple sclerosis, atrophic gastritis, inflammatory bowel diseases, and skin disorders such as vitiligo and psoriasis. This review aims to explore the overlap of T1D and other AIDs, focusing on the less common and lesser-known diseases. A better knowledge of these comorbidities may facilitate the identification of patients at risk to treat them in the preclinical period, before the onset of complications.

show abstract